SHANGHAI, 9. März 2026 /PRNewswire/ -- Das Jiahui International Cancer Center (JICC) hat einen US-Patienten mit fortgeschrittenem nicht-kleinzelligem Lungenkrebs (NSCLC) und Parkinson-Krankheit mit Ivonescimab stabilisiert, einer neuartigen Immuntherapie, die derzeit nur in China...
Hence then, the article about us patient mit fortgeschrittenem lungenkrebs durch neuartige immuntherapie behandlung in china stabilisiert was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( US-Patient mit fortgeschrittenem Lungenkrebs durch neuartige Immuntherapie-Behandlung in China stabilisiert )
Also on site :
- Sam's Club Delights Shoppers By Bringing Back One of its Top-Selling Snacks: 'I Am Completely Addicted'
- Anthropic says engineering missteps were behind Claude Code’s monthlong decline after weeks of user backlash
- 1990s Country King Shares Exciting Update on 2026 Tour: 'Let's Do This'